NCT04741334 is a clinical trial of direct anticoagulant in Craniocerebral Trauma, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Who is sponsoring NCT04741334?

NCT04741334 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

What drugs are being tested in NCT04741334?

Interventions in NCT04741334: direct anticoagulant, antiplatelet drugs, Dicumarols.

What condition does NCT04741334 study?

NCT04741334 studies Craniocerebral Trauma, Cerebral Hemorrhage.

Is NCT04741334 still recruiting?

NCT04741334 is currently completed. Last updated 31 March 2022.

Last reviewed 2022-03-31 · How we verify

NCT04741334

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mild Head Injury, Antiplatelets, and Anticoagulants

Completed Last updated 31 March 2022

What this trial tests

trial testing direct anticoagulant in Craniocerebral Trauma in 2,127 participants. Completed in 31 January 2022.

Timeline

27 September 2019

Primary endpoint
31 December 2021

31 January 2022

Quick facts

Lead sponsor	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,127
Start date	27 September 2019
Primary completion	31 December 2021
Estimated completion	31 January 2022
Sites	1 location across Italy

Drugs / interventions tested

direct anticoagulant
antiplatelet drugs — full drug profile →
Dicumarols — full drug profile →

Conditions studied

Craniocerebral Trauma — all drugs for Craniocerebral Trauma →
Cerebral Hemorrhage — all drugs for Cerebral Hemorrhage →

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Who can join

18 and older, any sex, with Craniocerebral Trauma or Cerebral Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Approximately 20% of patients with mild head injury presenting to the Emergency Department (ED) is taking antiplatelet agents and 10% is taking oral anticoagulants. The aim of the study is to determine the prevalence of cerebral hemorrhage in patients presenting to the ED with an MHI. It also aims to determine whether the use of antiplatelet agents and anticoagulants may be a risk factor for the occurrence of cerebral hemorrhage and mortality. This is a prospective observational study that will include all patients who present to ED at Gemelli Hospital for an MHI for 2 years. Patients will be divided into four groups according to whether or not they are taking anticoagulants and antiplatelet drugs. Groups will be compared to evaluate the possible increased risk of complications in patients on treatment and among the different medications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Craniocerebral Trauma

Currently open trials in the same condition.

NCT06632587 — Timing Impact of Early vs. Late Cranioplasty on Hemicraniectomy Outcomes · NA · recruiting
NCT06015451 — Exercise in Postconcussion Symptoms and Posttraumatic Headache · NA · recruiting

Other Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials

Trials by the same sponsor.

NCT07514572 — Impact of Estimated Weight and Height on Nutritional Assessment in Elderly · NA · not yet recruiting
NCT07504679 — Adipose Visceral and Epicardial Risk Evaluation · NA · not yet recruiting
NCT07520643 — MISTIC Study: Atherosclerosis, Neurocognition & Cardiovascular Signaling · not yet recruiting
NCT07479238 — Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy · not yet recruiting
NCT07494227 — Development of the SC-IBD Self-Care Measurement Scale · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04741334 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Last refreshed: 31 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04741334.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing